Share this article Share this article GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering (" MaxCyte" or the " Company"), today announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "offering"). The registration statement included a proposed change to the board of directors as well as unaudited financial information which is detailed below. Financial information in the Form S-1 registration statement The Company's Form S-1 registration statement contains unaudited consolidated financial statements for the period from 1 January 2021 to 31 March 2021 prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). Such consolidated financial statements, as extracted from the Form S-1 registration statement, are attached to this announcement.